Incyte INCY announced that the FDA has extended the review period for the supplemental new drug application (sNDA) for ruxolitinib cream. The sNDA is seeking approval of the cream for the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback